Navigation Links
Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations
Date:10/19/2015

SAN DIEGO, Oct. 19, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today the addition of Jeffrey Su, Ph.D., as Executive Vice President and Chief Operating Officer. Dr. Su will be responsible for all manufacturing operations at Sorrento, including the analytical and process development laboratories, the newly constructed cGMP manufacturing facility, and all required quality systems. 

"I am delighted that Dr. Su will join our management team. His appointment is a key addition to meet the needs of our current corporate growth and expansion of our business and pipeline programs. Dr. Su is a highly experienced executive with a proven track record of productivity and accomplishments in biological product development and manufacturing," said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. "He adds significant expertise in all areas of biological therapeutics development and manufacturing as well as in-depth knowledge of cGMP compliance requirements and the biologics regulatory environment. With our recent acquisition of four biosimilar/biobetter monoclonal antibodies and our internal antibody programs on track to enter clinical stage next year, Dr. Su will be a key stakeholder in these development processes. He will also lead the development efforts for all other immunotherapy products, including cellular therapies and chemically-modified proteins, such as antibody-drug conjugates, bispecific antibodies, as well as cell-internalizing antibodies and peptides."

Prior to joining Sorrento, Dr. Su was Chief Scientific and Development Officer at Cytovance Biologics Inc., a leading contract development and manufacturing company. He has successfully managed development projects involving partners in the US, Asia, Canada and Europe. Dr. Su has more than 23 years of experience in the Pharmaceutical and Biotech industry, including positions of increasing responsibility at Sanofi Pasteur, Femta Biopharmaceutical, Cancervax Corp., The Dow Chemical Company, Tanox Inc., and Human Genome Science Inc.  Dr. Su holds a Ph.D. in Chemistry from Carleton University, Canada, and a Master of Science degree in Chemistry from Nankai University, China.

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical stage biopharmaceutical company developing new treatments for cancer and associated pain and inflammation and autoimmune diseases. Sorrento recently licensed multiple late-stage biosimilar and biobetter antibodies for oncology and inflammation diseases for the US, European and Japanese markets. Sorrento recently sold the rights to Cynviloq™, which successfully completed the TRIBECA™ study, to NantPharma. The company is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist to treat terminal cancer patients suffering from intractable pain.

In December 2014, Sorrento and NantWorks formed a global joint venture, now called Immunotherapy NANTiBody, LLC, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., now renamed as NantKwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.  In July 2015, Sorrento and NantBioScience, Inc., a subsidiary of NantWorks, established a joint venture, called NantCancerStemCell, LLC to focus on the development of "first-in-class" small molecules against targets which may address important drivers of cancer growth including cancer stem cells. In August 2015, Sorrento entered into an exclusive licensing agreement to develop and commercialize 4 biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. Also in August 2015, TNK Therapeutics, a subsidiary of Sorrento, acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies. The CAR-T programs focus on targeting solid tumors as well as infectious diseases. In September 2015, Sorrento Therapeutics and City Of Hope announced the formation of a joint venture company, LA Cell, and the exclusive licensing by LA Cell of technology pioneered at City of Hope to develop first-in-class immunotherapies against intracellular targets ("cell internalizing antibodies").

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento's prospects, including, but not limited to any statements about the aforementioned cell penetrating technology and combinations of the cell penetrating technology with Sorrento's antibody library; LA Cell's business and technology prospects; chimeric antigen receptor (CAR) T cell programs; potential combination therapies, Sorrento's expectations for adoptive cellular immunotherapies, Sorrento's collaborations with NantKwest, NantCell, NantPharma, and NantBioScience, and the development of adoptive immunotherapies and the biosimilar/biobetter programs; Sorrento's ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; Sorrento's advances made in developing RTX, CAR.TNKs and human monoclonal antibodies using its proprietary G-MAB fully human antibody technology, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento™, G-MAB™, CAR.TNK™, TNK Therapeutics™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

 


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Sorrento Therapeutics And City Of Hope Announce Exclusive License To Develop First-In-Class Immunotherapies Against Intracellular Targets
2. Sorrento Therapeutics And Its Wholly-Owned Subsidiary, TNK Therapeutics, To Exclusively License CytoLuminas NanoVelcro Circulating Tumor Cell Profiling Assay
3. Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies
4. Sorrento Announces Departure of Mr. George Uy to become CEO of Start-up Company
5. Globavir Exclusively Licenses Oncology Program to Sorrento Therapeutics
6. Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes
7. Sorrento gründet Tochtergesellschaft TNK Therapeutics mit Fokus auf zelluläre Immuntherapien
8. Sorrento richt dochterbedrijf TNK Therapeutics op dat zich zal focussen op cellulaire immunotherapieën
9. Sorrento Establishes TNK Therapeutics Subsidiary with Focus on Cellular Immunotherapies
10. Sorrento Announces the Appointments of David H. Deming to the Board of Directors and Mark W. Durand as Chief Financial Officer
11. Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... ... sexual health, reproductive justice, contraception and consent with student and faculty from The ... health experts which included Francisco Ramirez, MPH; Elise Schuster, MPH; Raffaele M. Bernardo, ...
(Date:9/17/2019)... ... ... The Society to Improve Diagnosis in Medicine (SIDM) has been awarded a ... Seed Grant Program. The new program will engage healthcare organizations in efforts to identify, ... error. , SIDM will open the application process in January 2020 with decisions ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... for employers, became the first commercial teledentistry practice in the United States. Now, ... other hub entrepreneurs, company leaders, innovators and industry experts next week at CIC ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Warriors , with the goal of providing resources to assist researchers and encourage ... a progressive disease causing abnormal iron deposits in the brain. , BPAN ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... on the detection and treatment of infectious diseases at its annual Congress ... were noninvasive detection of residual HIV infected cell persistence and the development ...
(Date:9/11/2019)... ... , ... Workplace injuries cost individuals, organisations and society. Safety ... lead to musculoskeletal disorders (MSDs). , Starting with the individual and spreading ... Soter Analytics helps avoid ergonomic injury by coaching workers to self-correct their ...
(Date:9/11/2019)... ... September 11, 2019 , ... GRM Information Management, a leading ... and Information Conference in Chicago, Illinois September 14 to 18. , AHIMA ... GRM’s healthcare information management solutions . , Built around their robust, cloud-based ...
(Date:9/11/2019)... Calif. (PRWEB) , ... September 11, 2019 , ... Ahipoki ... This plant-based poke bowl option appeals to vegans, vegetarians, pescatarians and poke bowl ... sauce, sugar, and sesame oil. With its meaty texture similar to tuna, ...
Breaking Medicine News(10 mins):